April 7 2011 – UVM to conduct clinical trial for new idiopathic pulmonary fibrosis treatment

ImmuneWorks, Inc. recently partnered with The University of Vermont in Burlington to conduct a clinical trial for a new idiopathic pulmonary fibrosis (IPF) treatment. The Phase I clinical trial will evaluate the safety, tolerability, and biologic effects of three doses of IW001 in patients suffering from idiopathic pulmonary fibrosis (IPF), a serious lung disease.

Full Article:





This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>